Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Asahi Kasai to Integrate Japan and US Pharma Biz by March 2026
Asahi Kasei plans to integrate its pharmaceutical businesses in Japan and the US. The transition to the new scheme has already gotten underway since this fiscal year, with the company aiming to complete the process by the end of March…
To read the full story
Related Article
- Asahi Kasei Pharma Confident of Hitting FY2030 Group Sales Target: President
December 10, 2025
- Asahi Kasei to Buy Calliditas, Bag 1st Therapy for IgA Nephropathy
May 29, 2024
- Asahi Kasei Completes Acquisition of Veloxis
March 5, 2020
BUSINESS
- Keytruda Keeps Top Spot in Japan in April-June as Mounjaro Zooms: IQVIA
August 19, 2026
- LEO Pharma Buys Global Rights to Tanabe’s EPP/XLP Drug
August 19, 2026
- J-TEC to Explore Regenerative Medicine Licensing Opportunities in Taiwan
August 19, 2026
- Shionogi to Effectively Scrap Mandatory Retirement from FY2027
August 19, 2026
- Chugai Out-Licenses Anti-Dengue Antibody AID351 to GSK
August 19, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…